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Abstract
Context: There is evidence that heart rate variability (HRV) is reduced in major depressive disorder (MDD), although there is
debate about whether this effect is caused by medication or the disorder per se. MDD is associated with a two to fourfold
increase in the risk of cardiac mortality, and HRV is a robust predictor of cardiac mortality; determining a direct link between
HRV and not only MDD, but common comorbid anxiety disorders, will point to psychiatric indicators for cardiovascular risk
reduction.
Objective: To determine in physically healthy, unmedicated patients whether (1) HRV is reduced in MDD relative to controls,
and (2) HRV reductions are driven by MDD alone, comorbid generalized anxiety disorder (GAD, characterized by anxious
anticipation), or comorbid panic and posttraumatic stress disorders (PD/PTSD, characterized by anxious arousal).
Design, Setting, and Patients: A case-control study in 2006 and 2007 on 73 MDD patients, including 24 without anxiety
comorbidity, 24 with GAD, and 14 with PD/PTSD. Seventy-three MDD and 94 healthy age- and sex-matched control
participants were recruited from the general community. Participants had no history of drug addiction, alcoholism, brain
injury, loss of consciousness, stroke, neurological disorder, or serious medical conditions. There were no significant
differences between the four groups in age, gender, BMI, or alcohol use.
Main Outcome Measures: HRV was calculated from electrocardiography under a standardized short-term resting state
condition.
Results: HRV was reduced in MDD relative to controls, an effect associated with a medium effect size. MDD participants with
comorbid generalized anxiety disorder displayed the greatest reductions in HRV relative to controls, an effect associated
with a large effect size.
Conclusions: Unmedicated, physically healthy MDD patients with and without comorbid anxiety had reduced HRV. Those
with comorbid GAD showed the greatest reductions. Implications for cardiovascular risk reduction strategies in otherwise
healthy patients with psychiatric illness are discussed.
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Introduction
Major depressive disorder (MDD) and cardiovascular disease
(CVD) are leading burdens of disease worldwide, and there is
increasing recognition that the two are related. Up to 50% of
CVD patients suffer from depression [1], and depression
increases the risk for cardiac mortality two to four times,
irrespective of cardiac disease history [2–5]. Heart rate variability
PLoS ONE | www.plosone.org 1 February 2012 | Volume 7 | Issue 2 | e30777(HRV) – an index of the beat-to-beat changes in heart rate – is
one candidate mechanism underlying the link between depres-
sion, CVD, and sudden cardiac death (SCD) [6,7]. HRV is
mediated by the parasympathetic and sympathetic nerves and
reflects the capacity for the parasympathetic inhibition of
autonomic arousal. Increased HRV reflects a healthy autonomic
nervous system that is able to respond to changing environmental
circumstances [8,9]. By contrast, decreased HRV is a marker of
autonomic inflexibility [10] and ill-health [11], that may precede
more systemic problems such as inflammatory-mediated athero-
sclerosis and ventricular fibrillation [6], especially in younger
samples as reported on here.
Research has shown that depressed patients with CVD display
lower HRV than non-depressed patients [7]. There has been less
examination of the impact on HRV of depression without comorbid
physical illness. Using meta-analysis, we recently reported HRV
reductions in depressed patients without CVD [12]. We
interpreted these findings in the context of the polyvagal theory,
which highlights a role for the autonomic nervous system in the
somatomotor deficits and social impairment frequently observed in
depression. [8] However, findings on the impact of MDD on HRV
have been inconsistent; in particular, Licht et al. have reported
that HRV reductions are driven by medication effects alone
[13,14]. However, reviews [15,16] have argued that these
inconsistencies point to the need to control for (1) physical illness
such as CVD and diabetes; (2) medication status, which clearly
impacts on HRV, but needs to be distinguished from the
underlying effects of depression; (3) the presence of comorbid
anxiety; and (4) to select participants to avoid the need to
‘‘control’’ for confounding variables using ANCOVA when
participants are not randomly allocated to groups. These four
issues underpin core methodological aspects of the present study,
which are essential to isolate the effects of depression and
comorbid anxiety on HRV.
Another body of evidence suggests that anxiety – a condition
frequently comorbid with MDD in more than 60% of cases [17] –
rather than depression contributes to the reductions in HRV
[10,15,18] and CVD [19]. Intriguingly, patients with current
anxiety disorders display an almost threefold increase in the
prevalence of CVD, while no associations have been observed for
depressive disorders without comorbidity [19]. Although low
HRV has been reported in panic disorder (PD) and post-traumatic
stress disorder (PTSD) [18], studies have seldom examined the
impact of generalized anxiety disorder (GAD) on HRV [20].
While reduced HRV in PD [18] is consistent with the autonomic
features characteristic of panic attacks, reduced HRV in GAD
[10] may be driven by pre-attentive biases for threat information.
It remains to be determined which comorbid anxiety disorders
have the greatest impact on HRV, an important physiological
marker of cardiovascular risk [6].
This study examined the impact of MDD and comorbid anxiety
disorders on HRV to identify psychiatric indicators for cardiovas-
cular risk reduction. Our hypothesis was that HRV would be
reduced in MDD patients relative to age- and sex-matched
controls in an independent, physically healthy, and unmedicated
sample. Further, we sought to determine whether MDD without
comorbidity, MDD with GAD or MDD with PD and/or PTSD
display the greatest reductions in HRV. This is an important issue
given the frequent comorbidity of MDD with anxiety disorders
and competing accounts on the impact that anxiety with specific
features (arousal in PD and PTSD versus apprehension or worry in
GAD) may have on HRV [10,18].
Methods
Participants
Seventy-three patients with a primary diagnosis of MDD and 94
age- and sex-matched controls were included in this study.
Participants were recruited from the general community via self-
referral from advertisements and collaborating clinicians. We
obtained their data from the Brain Resource International
Database (BRID [21]; www.brainresource.com). The study was
approved by University of Sydney, Sydney West Area Health
Service, University of Adelaide and Flinders University human
research ethics committees, and all participants provided written
informed consent in accordance with the Australian National
Health and Medical Research Council guidelines.
Diagnoses were made by trained and supervised research
officers using the Mini-International Neuropsychiatric Interview
(MINI [22]) and the severity of clinical depression was assessed
using the structured interview guide for the Hamilton Depression
Rating Scale (SIGH-D [23]) (M=20.29, SD=4.34). Controls
were recruited through community advertising and were excluded
if they self-reported a history of psychiatric illness. Controls were
further screened for an Axis 1 disorder using the Somatic and
Psychological Health Report Questionnaire (SPHERE-12 [24]).
The SPHERE-12 is a self-report screening tool for common
mental disorders with acceptable validity and reliability [24,25].
All participants completed the Depression Anxiety and Stress
Scales (DASS-42 [26]), a reliable and valid self-report measure of
depression, anxiety, and stress severity [26,27] (Tables 1 and 2).
Participants had no history of drug addiction, alcoholism, brain
injury, loss of consciousness, stroke, neurological disorder, or other
serious medical conditions (e.g., CVD and diabetes). All
participants were free from anti-depressant medication for at least
five half-lives (70% of whom were drug-naive). Twenty-four
participants with MDD had comorbid GAD without other
diagnosis (‘‘anxious apprehension’’). Fourteen participants with
MDD had either comorbid PD (n=7), PTSD (n=4) or both
(n=3) (‘‘anxious arousal’’). No patient with comorbid PD and/or
PTSD had GAD.
Table 1. MDD and Control Group Characteristics (mean, S.D.).
Variable
MDD Group
(n=73)
Control Group
(n=94) P value
Age (SD) 36.5 (11.5) 35.7 (11.2) 0.64
Sex
Male, % 41.1 44.7 0.64
Female, % 58.9 53.3
DASS-42
Depression (SD) 27.2 (9.4) 2.1 (2.4) ,0.001
Anxiety (SD) 13 (10.9) 1.2 (1.8) ,0.001
Stress (SD) 22.2 (9.8) 4.5 (4.5) ,0.001
Body Mass Index 25.3 (4.6) 25.8 (5.4) 0.56
AUDIT-C 2 (2.9) 2.4 (3) 0.49
Abbreviations: MDD=major depressive disorder; GAD: generalised anxiety
disorder; PD: panic disorder; PTSD: posttraumatic stress disorder; DASS-42:
depression, anxiety and stress scales; SIGH-D: Structured Interview Guide for the
Hamilton Depression Rating Scale, AUDIT-C=alcohol use disorder identification
test consumption subscale.
doi:10.1371/journal.pone.0030777.t001
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Participants were seated in a sound- and light-controlled room
at 24uC and two 2-minute electrocardiogram (ECG) recordings
were collected during resting state. The data was sampled at
500 Hz, with 22-bit resolution digitization using a Compumedics
Neuroscan NuAmps amplifier and SCAN software, version 4.3.
Experimental studies have shown that 2-minute recordings are
predictive of coronary heart disease and mortality [28,29] and can
provide a more accurate picture of physiological changes than
longer-term recordings (which inevitably introduce variations from
a physiologically fixed state under laboratory conditions) [30,31].
Data Analysis
All data was manually inspected prior to analysis: data quality
was high, consistent with resting-state recording conditions. ECG
was analyzed using custom-developed software to perform semi-
automated pre-processing to remove noise from the ECG,
allowing for the identification of the R-peaks based on established
methods [32]. Cleaned R–R interval data was then imported into
Kubios software (available at: http://kubios.uku.fi) for calculation
of time, frequency and nonlinear measures. The two time-domain
measures calculated on the R–R intervals include the standard
deviation of R–R intervals (SDNN), and the square root of the
mean squared differences between successive R–R intervals
(RMSSD), a measure based on comparisons of lengths of adjacent
cycles. Two frequency domain measures were quantified: high
frequency (HF; 0.18–0.40 Hz), a measure of parasympathetic
activity; and the LF/HF ratio, a measure of sympathovagal
balance. We also examined two nonlinear domain measures: the
standard deviation of the Poincare ´ plot perpendicular to the line of
identity (PCSD1), and detrended fluctuation analysis (short-
fluctuation slope, DFAa1). The Poincare ´ graph plots each R–R
interval as a function of the next R–R interval, and the PCSD1
measure represents the short-term variability of the nonlinear
dynamic system and reflects parasympathetic nervous system
activity. DFA measures the correlation within the signal, and the
DFAa1 measures the short-range correlation between successive
R–R intervals. White Gaussian noise (a totally random signal) is
reflected in a value of 0.5; a Brownian noise signal (a signal in
which higher frequencies display decreased power) is reflected in a
value of 1.5 [33].
Table 2. Anxiety Subgroup Characteristics (mean, S.D.).
Variable MDD with GAD (n=24)
MDD with PD and/or PTSD
(n=14) MDD without anxiety (n=24)
Age (SD) 36.6 (11.7) 34.1 (12.1) 36.4 (10.6)
Sex
Male, % 45.8 50 58.3
Female, % 54.2 50 41.7
DASS-42
Depression (SD) 27.2 (11.5) 28.4 (7.9) 27.5 (8.9)
Anxiety (SD) 15.6 (10.6) 20 (11.5) 6.6 (6.1)
Stress (SD) 24.4 (10.2) 26.8 (7.2) 18.3 (9.8)
SIGH-D 21.5 (3.8) 20.3 (3) 18.5 (5.3)
Body Mass Index 24.2 (3.6) 27.5 (4.4) 25.8 (5.2)
AUDIT-C 1.5 (2.4) 2.2 (3.2) 2 (2.9)
doi:10.1371/journal.pone.0030777.t002
Figure 1. DASS-42 scale scores (mean ± standard deviation) for
MDD vs CTL (1a) and MDD groupings.
doi:10.1371/journal.pone.0030777.g001
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software (PASW) statistics, version 18. Independent-samples t-tests
on controls versus MDD, and one-way ANOVAs on controls
versus the three MDD groupings were conducted to determine
differences on age, gender, body mass index (BMI), and alcohol
use (Alcohol Use Disorders Test – Consumption Scale; AUDIT-C
[34]). ANOVAs were followed up by Tukey’s post-hoc tests.
Statistics were conducted on SIGH-D [23] and DASS-42 [26] to
confirm the validity of diagnostic groupings and determine
whether there were differences between patient groupings in
disorder severity (SIGH-D and DASS-42 depression scores). A
multivariate analysis of variance (MANOVA) was performed to
determine whether there were differences between MDD patients
and controls on an interpretable composite of HRV variables
across time, frequency, and nonlinear domains, and to provide a
control for multiple comparisons. A significant Pillai’s trace effect
for Group was followed by univariate analyses of variance
(ANOVAs) to identify which measures contribute to a significant
multivariate effect. Effect size measures (Cohen’s d) relating to the
difference between patient groups and controls were determined.
Figure 2. Time (row 1), frequency (row 2) and non-linear (row 3) domain measures of HRV in unmedicated patients with major
depressive disorder (MDD) relative to controls (CTL).
doi:10.1371/journal.pone.0030777.g002
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Group Characteristics
Table 1, Table 2 and Figure 1 present participant character-
istics. There were no group differences on age, gender, BMI, or
alcohol use. As expected, all patient groupings differed from
controls on depression (p,.001), anxiety (p,.001) and stress
(p,.001) scales (Table 1, Figure 1a). No differences were observed
between different patient sub-groupings on SIGH-D or self-
reported patient DASS-42 depression severity (Table 2, Figure 1b),
nor between MDD patients with GAD and those with comorbid
PD and/or PTSD on self-reported measures of anxiety or stress.
Patient groups with comorbid anxiety differed from those without
anxiety on DASS-42 measures of anxiety (p,.001) and stress
(p,.03), but not depression (Table 2, Figure 1b).
Heart Rate Variability
Our hypothesis that HRV is reduced in MDD relative to
controls (CTL) was confirmed by an overall MANOVA, including
all HRV measures [F(12,154)=2.992, p=.001, partial eta
squared=.189] (Figure 2). Strikingly, the partial eta squared
value indicated that 19% of the variance in HRV is attributable to
MDD. MANOVA also identified significant differences between
MDD groups with comorbid GAD (anxious anticipation), comorbid
PD and/or PTSD (anxious arousal), MDD without anxiety
comorbidity, and healthy control groups [F(36,417)=1.780,
p=.005, partial eta squared=.131]. Figure 3 shows linear
decreases in all measures of HRV (with the exception of the
LF/HF ratio); these decreases are most pronounced in MDD
patients with comorbid GAD, followed by patients with comorbid
PD and/or PTSD, and MDD patients without anxiety relative to
controls. ANOVAs are reported below to identify which measures
contribute to these significant multivariate effects.
Heart Rate Variability: MDD Versus Control Groups
These results are shown in Figure 2. In time-domain measures,
the MDD group displayed reductions in RMSSD (F (165)=9.41,
p=0.003, Cohen’s d=20.48) and SDNN (at trend levels) (F
Figure 3. Time (row 1), frequency (row 2) and non-linear (row 3) domain measures of HRV in controls, MDD without anxiety, MDD
with comorbid PD and/or PTSD and MDD patients with GAD.
doi:10.1371/journal.pone.0030777.g003
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measures, the groups differed on HF (F (165)=8.712, p=0.004,
Cohen’s d=20.46) and LF/HF ratio (F (165)=7.71, p=0.006,
Cohen’s d=0.42). Although the LF/HF ratio was increased in
MDD relative to CTL, this finding is interpreted as an increase in
sympathetic relative to parasympathetic activity in MDD,
consistent with a decrease in HRV. In nonlinear-domain
measures, the groups differed on PCSD1 (F (165)=9.35,
p=0.003, Cohen’s d=20.48) and DFAa1 (F (165)=11.30,
p=0.001, Cohen’s d=0.52). Although the DFAa1 measure is
increased in MDD relative to CTL, this finding indicates that the
MDD group displays a less random signal than CTL, consistent
with a reduction in HRV.
Heart Rate Variability: All Four Groups
These results are shown in Figure 3. In time-domain measures,
ANOVA revealed a statistically significant difference for RMSSD
[F(3, 152)=4.8, p=.003, g
2=.09] and SDNN (at trend levels)
[F(3, 152)=2.58, p=.06, g
2=.05]. Post-hoc comparisons re-
vealed that RMSSD is reduced in MDD patients with GAD
(p=.004, Cohen’s d=.835). No other patient groups differed from
each other or from controls.
In frequency-domain measures, ANOVA revealed a statistically
significant difference for HF [F(3,152)=4.6, p=.004, g
2=.08]
and LF/HF ratio [F(3, 152)=4.1, p=.008, g
2=.08]. Post-hoc
comparisons revealed that HF (p=.003, Cohen’s d=.854) was
reduced and LF/HF ratio (p=.028, Cohen’s d=.943), increased
in MDD patients with GAD, relative to controls. MDD patients
with no anxiety also displayed increased LF/HF ratio relative to
controls at trend levels (p=.051, Cohen’s d=.661). No other
significant differences were observed.
In nonlinear-domain measures, ANOVA revealed a statistically
significant difference for PCSD1 [F(3, 152)=4.7, p=.003,
g
2=.09] and DFAa1 [F(3, 152)=6, p=.001, g
2=.11]. Post-hoc
comparisons revealed that PCSD1 (p=.004, Cohen’s d=2.834)
decreased and DFAa1 ratio (p=.002, Cohen’s d=.958) increased
in MDD patients with GAD, relative to controls. MDD patients
with PD and/or PTSD also displayed a statistical trend towards
increased DFAa1 ratio (p=.063, Cohen’s d=.744) No other
significant differences were observed.
Discussion
Recent debate [35–38] has focused on inconsistent findings
concerning whether HRV is reduced in depression per se [12], or
whether these reductions are driven by antidepressant medication
[14]. We found that HRV is reduced in unmedicated patients
diagnosed with MDD without CVD across a variety of measures,
an effect associated with a medium effect size. Other lines of
evidence [10,15] have suggested that anxiety rather than
depression drives the reported HRV reductions in MDD, although
until now, specific comorbid anxiety disorders that have the
greatest impact on HRV have not been identified. Our findings
indicate that HRV is most reduced in comorbid GAD, and that
these reductions were not due to depression severity – all MDD
groupings rated similarly on levels of depression severity – or other
potential confounding variables such as age, BMI, alcohol use, and
physical illness including diabetes and CVD. The advantages of
the current study are (i) the exclusion of medicated patients and
those with comorbid physical illness, (ii) the subgrouping of
patients with and without anxiety disorders, (iii) the careful
selection of participants to avoid the need for ANCOVA and (iv)
the inspection of a variety of HRV variables.
GAD is characterized by anxious apprehension and worry,
involving pre-attentive biases to threat information, and rigid and
inflexible response patterns [39]. The findings of the current study
indicate that depressed patients with a secondary diagnosis of
GAD had the largest decreases in HRV, and the large effect sizes
observed highlight the clinical relevance of this effect. A recent
study on HRV [13], examined the impact of current anxiety
disorders (n=1159), including GAD (38.2% of the sample), PD
(55.4%) and social phobia (55.5%), relative to controls (n=616),
reporting that while patients had lower SDNN and respiratory
sinus arrhythmia, no differences were observed between the
anxiety disorders, and the effects disappeared after adjustment for
antidepressant use. We have raised a number of concerns over the
findings reported by Licht and colleagues elsewhere [16,35,36],
and simply note here that while the sample size of the study is
impressive, a number of methodological issues may account for
their findings. The current study provides an important extension
to prior work [10,20], indicating that comorbid anxiety is
associated with the greatest reductions in HRV and that patients
Figure 4. Proposed model for reduced heart rate variability
(HRV) in patients with major depressive disorder (MDD) and
comorbid generalised anxiety disorder (GAD). These patients
typically experience worry and hypervigilance to threat, leading to a
chronic withdrawal of the parasympathetic nervous system (PNS) and
long-term reductions in HRV, placing these patients at an increased risk
for cardiovascular disease (CVD) and sudden cardiac death (SCD).
doi:10.1371/journal.pone.0030777.g004
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reduction strategies such as behavioural modification, exercise and
addressing other risk factors (e.g. smoking and moderating alcohol
use). While it is possible that patients characterized by anxious
arousal may display greater reductions during emotional challenge
(e.g., stress), short-term resting-state measures of HRV better
reflect intrinsic HRV [30].
There are a number of explanations for why HRV may be
reduced in depression and in those with comorbid GAD in
particular. One potential explanation proposed for the link
between anxiety, HRV and CVD is the inability to disengage
threat detection, which serves to perpetuate worry and hypervig-
ilance, even when no real threat exists [10]. Reductions in
parasympathetic tone may be a consequence of reduced activation
within the central autonomic network (CAN) [9], a network of
brain regions that control a variety of visceromotor, neuroendo-
crine, and behavioral responses critical for goal-directed behavior
and behavioral flexibility. Neuroimaging studies report that
decreases in HRV are associated with concomitant decreases in
activation in a number of brain regions, including the right
superior prefrontal (BA 8, 9), left rostral anterior cingulate (BA 24,
32), right dorsolateral prefrontal (BA 46), and right parietal (BA
40) cortices [9]. The neurovisceral integration model highlights a
role for the prefrontal cortex – particularly the orbitofrontal and
medial prefrontal cortices – in vagally mediated cardiovascular
control. HRV appears to index the functional integrity of the CAN
and may underpin successful adjustment, self-regulation, and
psychological flexibility in response to environmental demands [9].
Therefore, the reductions observed in MDD patients with
comorbid GAD may be associated with prolonged prefrontal
inactivity, disinhibition of the central nucleus of the amygdala, and
activation of medullary cardioacceleratory circuits [9]. Our results
suggest that patients with MDD and comorbid GAD, a disorder
characterized by worry and hypervigilance, may have difficulty
disengaging from threat detection, which may lead to a chronic
withdrawal of parasympathetic nervous system activity, over-
activation of sympathetic nervous system activity, and long-term
reductions in HRV, subsequently increasing the risk for CVD and
SCD (Figure 4).
It is possible that the observed HRV reductions were due to
potential lifestyle factors not assessed in the current study, such as
smoking or low physical activity levels in the depressed patients.
While it is possible that these factors could explain the differences
observed between MDD patients and controls, it is unlikely they
could explain the differential effects observed for patient sub-
groupings relative to controls. Recent work also highlights a
relationship between HRV and inflammatory markers [40,41]
such as interleukin-6 (IL-6) and C-reactive protein (CRP). This is
important because inflammation also plays a role in the
pathogenesis of CVD. While we did not collect this information,
our study reports on a much younger cohort than these studies,
and as age is a well-established cardiovascular disease risk factor
associated with an increasing inflammatory burden [42], it is less
likely that changes in these parameters would be observed in our
sample. Regardless, autonomic imbalance is considered to be a
final common pathway to increased morbidity and mortality [43].
While acetylcholine released from the vagus inhibits proinflam-
matory cytokine production, reduced vagal tone (reflected as
reductions in HRV) leads to a heightened inflammatory state, and
development of CVD [6,44]. We suggest therefore that changes in
HRV may precede the development of these other critical,
‘downstream’ risk markers, particularly in younger samples.
In conclusion, this study has provided strong evidence that
clinicians should consider comprehensive cardiovascular risk-
reduction strategies for MDD patients with comorbid GAD in
particular. Further research examining intermediate (HRV) (as
well as final endpoints such as mortality rate) is required to confirm
whether such strategies are needed for patients with MDD alone,
and MDD with comorbid PD and/or PTSD.
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